Market

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025
Read More

Related Posts

Oil heads for first monthly drop since November as economic uncertainty weighs

Oil heads for first monthly drop since November as econ...

Virgin Galactic’s new spacecraft looms large as company eyes future profitability

Virgin Galactic’s new spacecraft looms large as company...

Canada watchdog probing X's use of personal data in AI models' training

Canada watchdog probing X's use of personal data in AI ...

Social Security Administration announces ‘massive’ reorganization, ‘significant’ job cuts

Social Security Administration announces ‘massive’ reor...

Autodesk says it’s cutting 9% of its workforce, and shares rise

Autodesk says it’s cutting 9% of its workforce, and sha...

Alliance Entertainment CEO Jeffrey Walker buys $2.69 billion in stock

Alliance Entertainment CEO Jeffrey Walker buys $2.69 bi...